Laura Paris

Laura Paris

Auto-generated profile, based on publicly available information

Laura Paris

Department of Oncology and Hematology, Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

20 September 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LBLuca Bertamini
Luca Bertamini
SOStefania Oliva
Stefania Oliva
DRDelia Rota-Scalabrini
Delia Rota-Scalabrini
LPLaura Paris
Laura Paris
SMSonia Morè
Sonia Morè
Francesca GayFrancesca Gay
Francesca Gay
PURPOSE: High levels of circulating tumor plasma cells (CTC-high) in patients with multiple myeloma are a marker of aggressive disease. We aimed to confirm the prognostic impact and identify a possible cutoff value of CTC-high for the prediction of progression-free survival (PFS) and overall survival (OS), in the context of concomitant risk features and minimal residual disease (MRD) achievement.METHODS: CTC were analyzed at diagnosis with two-tube single-platform flow cytometry (sensitivity 4 × 10–5) in patients enrolled in the multicenter randomized FORTE clinical trial (ClinicalTrials.gov identifier: NCT02203643 ). MRD was assessed by second-generation multiparameter flow cytometry (sensitivity 10–5). We tested different cutoff values in series of multivariate (MV) Cox proportional hazards regression analyses on PFS outcome and selected the value that maximized the Harrell's C-statistic. We analyzed the impact of CTC on PFS and OS in a MV analysis including baseline features and MRD negativity.RESULTS: CTC analysis was performed in 401 patients; the median follow-up was 50 months (interquartile range, 45-54 months). There was a modest correlation between the percentage of CTC and bone marrow plasma cells ( r = 0.38). We identified an optimal CTC cutoff of 0.07% (approximately 5 cells/µL, C-index 0.64). In MV analysis, CTC-high versus CTC-low patients had significantly shorter PFS (hazard ratio, 2.61; 95% CI, 1.49 to 2.97, P < .001; 4-year PFS 38% v 69%) and OS (hazard ratio, 2.61; 95% CI, 1.49 to 4.56; P < .001; 4-year OS 68% v 92%). The CTC levels, but not the bone marrow plasma cell levels, affected the outcome. The only factor that reduced the negative impact of CTC-high was the achievement of MRD negativity (interaction P = .039).CONCLUSION: In multiple myeloma, increasing levels of CTC above an optimal cutoff represent an easy-to-assess, robust, and independent high-risk factor. The achievement of MRD negativity is the most important factor that modulates their negative prognostic impact.

Verified
Journal Article
Open access
PDF file
AWAnna Waszczuk-Gajda
Anna Waszczuk-Gajda
OPOlaf Penack
Olaf Penack
GSGiulia Sbianchi
Giulia Sbianchi
LKLinda Koster
Linda Koster
DBDidier Blaise
Didier Blaise
GBGrzegorz Wladyslaw Basak
Grzegorz Wladyslaw Basak
Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0–100 days, 101 days–1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4–108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1–7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3–5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.

7 January 2026 in Leukemia
Verified
Journal Article
Open access
PDF file
NBNoffar Bar
Noffar Bar
TMThomas Martin
Thomas Martin
CHCraig C Hofmeister
Craig C Hofmeister
María Victoria MateosMaría Victoria Mateos
María Victoria Mateos
MHMarkus Hansson
Markus Hansson
LCLuciano J. Costa
Luciano J. Costa
B-cell maturation antigen (BCMA)-targeting therapies provide a new approach to treating multiple myeloma (MM). Alnuctamab (ALNUC) is a 2 + 1 immunoglobulin G1-based bispecific antibody binding BCMA and CD3ε receptors on myeloma and T cells, respectively. CC-93269-MM-001 is a first-in-human, phase 1 dose escalation/expansion study investigating ALNUC in relapsed/refractory MM. Patients had ≥3 prior regimens, disease progression ≤60 days of last regimen, and were BCMA-directed therapy-naïve. ALNUC was administered intravenously (IV) and subcutaneously (SC); however, SC was selected for further evaluation due to the more favorable safety profile. Ninety-five patients received ALNUC SC; at data cutoff, 44.2% remained on treatment and median follow-up was 8.0 months. The recommended phase 2 dose was 30 mg. The most common treatment emergent adverse events (any grade/grade 3/4) were CRS (57.9%/0%), and neutropenia (53.7%/43.2%). Infections were also frequent (64.2%/14.7%). ORR was 58.9% for all ALNUC SC-treated patients and 71.4% for the 30-mg cohort; 47/95 (49.5%) were measurable residual disease (MRD) negative. Overall, the safety and efficacy of ALNUC SC were comparable to other BCMA-targeted therapies. These results support improved safety of SC versus IV, and corroborate a step-up dosing strategy to mitigate CRS. Importantly, a schedule that de-intensifies over time provides favorable toxicity that may be applicable to other bispecific engagers.

7 December 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
Roberto MinaRoberto Mina
Roberto Mina
AFAntonietta Pia Falcone
Antonietta Pia Falcone
SBSara Bringhen
Sara Bringhen
ALAnna Marina Liberati
Anna Marina Liberati
NPNorbert Pescosta
Norbert Pescosta
Alessandra LaroccaAlessandra Larocca
Alessandra Larocca

31 March 2025 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Open access
LCLorenzo Cani
Lorenzo Cani
MPMaria Teresa Petrucci
Maria Teresa Petrucci
KMKatia Mancuso
Katia Mancuso
RZRenato Zambello
Renato Zambello
LPLaura Paris
Laura Paris
MDMattia D’Agostino
Mattia D’Agostino
Fluorescence in situ hybridization (FISH) is the standard technique for the prognostic detection of cytogenetic abnormalities (CA) in multiple myeloma (MM). In Italy, the application of practical guidelines for FISH testing in clinical studies and the degree of standardization of laboratory techniques are largely unknown. We conducted a survey from April to July 2023 among 70 MM-treating centers associated with the European Myeloma Network Italy and geographically well distributed across Italy. We aimed to record laboratory and clinicians' perspectives about FISH application in Italy, with a focus on 1q alterations. FISH was widely accessible across the country, with 71% of centers performing it locally, while the remaining centers (predominantly those with 80 years). At relapse, 53% of centers routinely repeated FISH testing, 9% did not, while others repeated it selectively. This overview of FISH use in Italy provides a basis for future standardization efforts.